Daewon Pharmaceutical's Quadruple Obesity Drug Shows 50% Weight Reduction in Preclinical Trials
Data on GLP-1, GIP, GCG, and Gastrin Quadruple Agonist to Be Unveiled at ADA 2026
Fasting Blood Glucose Reduced from 223 to 70 mg/dL
Daewon Pharmaceutical will release results showing that its quadruple agonist-based obesity treatment candidate, currently under development, reduced body weight by more than 50% and lowered fasting blood glucose levels to as low as 70 mg/dL in preclinical trials.
Daewon Pharmaceutical announced on June 4 that it will present the preclinical research results of a GLP-1/GIP/GCG/Gastrin quadruple agonist, co-developed with Pharmus Bioscience, at the American Diabetes Association (ADA 2026) conference, which will be held in New Orleans, United States, from June 5 to 8 (local time).
This drug candidate is a quadruple agonist that adds a gastrin receptor activation mechanism to GLP-1, GIP, and GCG. It is being developed not only for weight loss but also with the goal of protecting pancreatic beta cells and improving kidney function.
According to the preclinical results, administration of the drug to diet-induced obese mouse models resulted in more than 50% reduction in body weight compared to the control group after 22 days. Fasting blood glucose levels also improved. While the control group had fasting blood glucose levels of 223 mg/dL, the group administered the candidate drug showed reductions to as low as 70 mg/dL. At the conference, Daewon Pharmaceutical plans to present detailed data on the multi-agonist design, receptor activation markers, and changes in body weight, food intake, and blood glucose levels.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Juil Kim, Executive Vice President of R&D at Daewon Pharmaceutical, stated, "By integrating the gastrin mechanism, we are developing a metabolic disease treatment that aims not only for weight loss but also for recovery of organ function."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.